A serum-free Vero production platform for a chimeric virus vaccine candidate - Wikidata - wikimedia - TriplyDB

A serum-free Vero production platform for a chimeric virus vaccine candidate

A serum-free Vero production platform for a chimeric virus vaccine candidate

http://www.wikidata.org/entity/Q30462034

about

Serum-free microcarrier based production of replication deficient influenza vaccine candidate virus lacking NS1 using Vero cells.A single amino acid in the F2 subunit of respiratory syncytial virus fusion protein alters growth and fusogenicity.

P2860

Q30474419-EB81A9DC-DFFF-47C5-BAAA-982BE4F60FDE Q37332290-79D9548C-195B-4125-806B-92C3832F3A13

P2860

A serum-free Vero production platform for a chimeric virus vaccine candidate

http://www.wikidata.org/entity/Q30462034

description

2006 nî lūn-bûn

@nan

2006 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2006 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2006年の論文

@ja

2006年論文

@yue

2006年論文

@zh-hant

2006年論文

@zh-hk

2006年論文

@zh-mo

2006年論文

@zh-tw

2006年论文

@wuu

name

A serum-free Vero production platform for a chimeric virus vaccine candidate

@ast

A serum-free Vero production platform for a chimeric virus vaccine candidate

@en

type

label

A serum-free Vero production platform for a chimeric virus vaccine candidate

@ast

A serum-free Vero production platform for a chimeric virus vaccine candidate

@en

prefLabel

A serum-free Vero production platform for a chimeric virus vaccine candidate

@ast

A serum-free Vero production platform for a chimeric virus vaccine candidate

@en

P1433

Q30462034-A2A50567-CAA0-4535-910E-18693E5FEFB2

P1476

Q30462034-A5698A66-ADCA-4D3E-8705-D81BFD7C2A9A

P2093

Q30462034-0D05B493-32B8-4E0E-B35B-00E8CC7EC077

Q30462034-1FF0D0F2-D506-4836-9B4D-E1422C7FD31D

Q30462034-2B19B087-0A84-4B6D-8BF5-9A99575FF9F9

Q30462034-3022F37C-772F-4688-A34F-07CB0CC00D98

Q30462034-4154EDF4-B4C4-46A9-AFED-74E689FF30A8

Q30462034-74AEB5D2-8065-4CFF-9364-972412726F0F

Q30462034-9DEFD6C0-AEEC-49F6-9859-1255A3207CC4

Q30462034-B3E9F509-F0D6-4EB7-A722-535E51CDB4DB

Q30462034-D077F3D5-8C63-44F6-9E3B-FF447279626E

P2860

Q30462034-083E7670-7A4C-4728-853F-5579266FBFD0

Q30462034-0CF130D3-3AD6-4093-B8F9-4D24DDAB6D16

Q30462034-2038F862-C02D-44B4-BCD9-21D1AF6DD027

Q30462034-2988FD2D-9C7E-4CD3-9262-790D64814A80

Q30462034-2D2B8809-EB79-4571-8068-F50BAAF63120

Q30462034-411B924E-F809-4AE1-9D9E-ECFD40C19AA8

Q30462034-43D4DA26-D71D-428C-8FF2-CC9293013294

Q30462034-4E701A61-968D-4C19-A21C-EA2699CCD179

Q30462034-4F1C1041-F08F-4747-A0BE-14E4A15ED3C0

Q30462034-51957ACB-A418-4D75-892C-CA8324EFC885

P2888

Q30462034-9919C27C-35CB-46A7-B761-D0D9FF4B0397

P304

Q30462034-6080E1C3-B757-4265-B9E1-3410EFE200D2

P31

Q30462034-161CEC68-1440-4210-9B8B-08007131EE7D

P356

Q30462034-F29E1D29-E25D-47D5-8831-8E5DE8786C7F

P433

Q30462034-3C13A286-BA19-4608-8196-FF015CC9021B

P478

Q30462034-07837876-4283-4387-B799-6FE56A3C5228

P577

Q30462034-708CFD75-2811-4630-AB65-0A713E5FEAB8

P5875

Q30462034-649C350B-9849-4736-B979-CBC4D612819F

P6179

Q30462034-02ADA114-2BD7-486D-B083-2ABB5025C2AD

P698

Q30462034-DA56CBBE-D59D-4B50-BDD3-18A3E8ADD196

P932

Q30462034-7B96DA0D-12F7-42AA-BCBC-46A506FB427E

P356

S10616-006-9030-7

P1433

P1476

A serum-free Vero production platform for a chimeric virus vaccine candidate

@en

P2093

Armida Cortez

http://www.w3.org/2001/XMLSchema#string

Danny Liebertz

http://www.w3.org/2001/XMLSchema#string

Gina B Lin

http://www.w3.org/2001/XMLSchema#string

Hui Ju

http://www.w3.org/2001/XMLSchema#string

Inesse Sifi

http://www.w3.org/2001/XMLSchema#string

Inn H Yuk

http://www.w3.org/2001/XMLSchema#string

J Michael Berry

http://www.w3.org/2001/XMLSchema#string

Richard M Schwartz

http://www.w3.org/2001/XMLSchema#string

Yvonne Lam

http://www.w3.org/2001/XMLSchema#string

P2860

Specific association of glycoprotein B with lipid rafts during herpes simplex virus entry

Identification of mutations contributing to the temperature-sensitive, cold-adapted, and attenuation phenotypes of the live-attenuated cold-passage 45 (cp45) human parainfluenza virus 3 candidate vaccine.

Summary and conclusion. Animal sera, animal sera derivatives and substitutes used in the manufacture of pharmaceuticals.

The transmissible spongiform encephalopathy agents: concerns and responses of United States regulatory agencies in maintaining the safety of biologics.

Respiratory syncytial virus and parainfluenza virus.

Production of adenovirus vector for gene therapy.

Development and optimization of an adenovirus production process.

Transmissible spongiform encephalopathies and tissue cell culture.

Parainfluenza virus type 3 expressing the native or soluble fusion (F) Protein of Respiratory Syncytial Virus (RSV) confers protection from RSV infection in African green monkeys.

Expression of the surface glycoproteins of human parainfluenza virus type 3 by bovine parainfluenza virus type 3, a novel attenuated virus vaccine vector

P2888

s10616-006-9030-7

P304

183-192

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S10616-006-9030-7

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

51

http://www.w3.org/2001/XMLSchema#string

P577

2006-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

23467335

http://www.w3.org/2001/XMLSchema#string

P6179

1045793605

http://www.w3.org/2001/XMLSchema#string

P698

19002888

http://www.w3.org/2001/XMLSchema#string

P932

3449809

http://www.w3.org/2001/XMLSchema#string